Arteaga Edmundo, Araujo Aloir Queiroz, Buck Paula, Ianni Barbara Maria, Rabello Rogerio, Mady Charles
Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Am Heart J. 2005 Dec;150(6):1228-32. doi: 10.1016/j.ahj.2005.02.045.
Plasma B-type natriuretic peptide (BNP) is a sensitive functional marker in heart disease including hypertrophic cardiomyopathy (HCM). The utility of plasma amino-terminal pro-BNP (NT-proBNP) quantification in heart disease has been investigated, but there are no published data regarding this test in HCM.
Plasma NT-proBNP was assessed in 71 patients with HCM and in 40 healthy subjects. Symptomatic status was assessed according to the New York Heart Association classification. M-mode and Doppler echocardiographic data were obtained in all patients and healthy subjects to study their correlations and comparisons (Spearman and Mann-Whitney tests).
Median NT-proBNP was 848 pg/mL in patients and 28 pg/mL in the control group (P < .0001). Patients in New York Heart Association functional class I/II had a median NT-proBNP of 669 pg/mL as compared with 3357 pg/mL for patients in class III/IV (P < .0001). Amino-terminal pro-BNP levels correlated positively with left atrial diameter (r = 0.40, P = .0005), septal thickness (r = 0.35, P = .002), and mitral flow velocity/mitral annulus velocity (E/Ea) ratio (r = 0.42, P < .0001). There was a weak correlation with obstruction (r = 0.23, P = .05), and a significant difference in the medians was observed between obstructive (1651 pg/mL) and nonobstructive (669 pg/mL) HCM groups (P = .01). Patients with Doppler E/Ea ratios > or = 10 had higher NT-proBNP levels than patients with E/Ea < 10 (P < .0001). Multivariate analysis showed that NT-proBNP correlated independently with left atrial diameter (P < .01), hypertrophy (P < .01), and E/Ea (P < .01).
In HCM, plasma NT-proBNP levels are elevated and correlate positively with symptoms of heart failure, hypertrophy severity, and Doppler echocardiographic signs of left ventricular diastolic dysfunction. Further studies are necessary to assess the usefulness of the test in clinical practice and its role as a prognostic marker.
血浆B型利钠肽(BNP)是包括肥厚型心肌病(HCM)在内的心脏病的一种敏感功能标志物。已对血浆氨基末端前脑钠肽(NT-proBNP)定量检测在心脏病中的应用进行了研究,但尚无关于该检测在HCM中的已发表数据。
对71例HCM患者和40名健康受试者进行血浆NT-proBNP评估。根据纽约心脏协会分类评估症状状态。在所有患者和健康受试者中获取M型和多普勒超声心动图数据,以研究它们的相关性和比较情况(Spearman和Mann-Whitney检验)。
患者的NT-proBNP中位数为848 pg/mL,对照组为28 pg/mL(P <.0001)。纽约心脏协会功能分级为I/II级的患者NT-proBNP中位数为669 pg/mL,而III/IV级患者为3357 pg/mL(P <.0001)。氨基末端前脑钠肽水平与左心房直径呈正相关(r = 0.40,P =.0005)、与室间隔厚度呈正相关(r = 0.35,P =.002)以及与二尖瓣血流速度/二尖瓣环速度(E/Ea)比值呈正相关(r = 0.42,P <.0001)。与梗阻呈弱相关(r = 0.23,P =.05),在梗阻性(1651 pg/mL)和非梗阻性(669 pg/mL)HCM组之间观察到中位数有显著差异(P =.01)。多普勒E/Ea比值≥10的患者NT-proBNP水平高于E/Ea < 10的患者(P <.